Compromised drug lot impacts Jasper's chronic hives study, stock falls
Jasper Therapeutics’ stock crashed on Monday morning after the biotech said issues with a drug product lot impacted data in a Phase 1b/2a clinical trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.